Ionis Pharmaceuticals (IONS) said Monday that a study of olezarsen in people with moderate hypertriglyceridemia with or at risk for atherosclerotic cardiovascular disease met its primary endpoint, as well as all key secondary endpoints.
Results showed a "statistically significant" placebo-adjusted 61% and 58% reduction in triglyceride levels at six months with the 80-milligram and 50 mg monthly doses, respectively, the company said.
Olezarsen also showed a favorable safety and tolerability profile, according to Ionis.
The company expects data from the pivotal phase 3 CORE and CORE2 studies assessing olezarsen to treat severe hypertriglyceridemia in Q3.
Triglycerides are a kind of fat the body uses as a source of energy.
Ionis shares were up 1% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。